Olympus Co. (OTCMKTS:OLYMY – Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 29,921 shares, a growth of 497.9% from the September 15th total of 5,004 shares. Based on an average trading volume of 71,032 shares, the short-interest ratio is presently 0.4 days.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group lowered shares of Olympus from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the company has an average rating of “Hold”.
Read Our Latest Report on Olympus
Olympus Stock Performance
About Olympus
Olympus Corporation is a Japan-based medical technology company that develops and manufactures equipment and systems used in minimally invasive procedures. Its primary business focuses on endoscopy and therapeutic solutions for hospitals, physicians and other health care providers.
The company’s products include gastrointestinal endoscopes and related imaging systems, surgical visualization equipment, electrosurgical devices and treatment instruments. Olympus also provides solutions used in urology, gynecology, respiratory care and ear, nose and throat procedures, along with service, training and other support for its medical technology portfolio.
Founded in 1919 as Takachiho Corporation, the company adopted the Olympus name in 1949 and historically operated businesses in cameras, audio products and scientific equipment.
Further Reading
- Five stocks we like better than Olympus
- 3 Unique ETFs With Strong Momentum for the End of the Year
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
